Bristol-Myers Squibb’s acquisition of Cardioxyl Pharmaceuticals and its prodrug used to treat heart failure earned top honors in the Mergers and Acquisitions category from Thomson Reuters’ Allicense event on June 8.
Johns Hopkins Technology Ventures and a visiting researcher from the National Institutes of Health helped put the Johns Hopkins University scientists who compose the startup in touch, which led to the creation of Cardioxyl Pharmaceuticals.
{iframe}http://ventures.jhu.edu/good-news-august-2016/{/iframe}